An FT investigation has found a thriving market for stem cell therapies in the US promising longer, healthier lives. Experts say such claims are dangerous
Related stories
Nvidia and AMD shares fall as new AI announcements fail to re-energize investors
Why Ciena, Lumentum and other optical stocks were among the market’s biggest losers on Monday
Bosnia warns US of pro-Russia Serb enclave’s lobbying efforts
Meta is back on the AI leaderboard with its new family of Wonder models
Trump’s ‘energy ceasefire’ collides with real-world problems of dwindling fuel supplies
Houthi assault on Saudi airports strikes at MBS’s economic vision